{{drugbox
| Verifiedfields = changed
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = K7G81N94DT
| verifiedrevid = 444359019
| IUPAC_name        = ''N''-(1-{3-[(3''R'')-1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl}-4-phenylpiperidin-4-yl]-''N''-methylacetamide
| image             = Osanetant.png
| width             = 220
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number        = 160492-56-8
| CAS_supplemental  = 
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 219077
| IUPHAR_ligand = 2110
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          = 
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 346178
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 189901
| C=35|H=41|Cl=2|N=3|O=2
| molecular_weight  = 606.625 g/mol
| smiles            = CC(=O)N(C)C1(CCN(CC1)CCC[C@@]2(CCCN(C2)C(=O)C3=CC=CC=C3)C4=CC(=C(C=C4)Cl)Cl)C5=CC=CC=C5
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C35H41Cl2N3O2/c1-27(41)38(2)35(29-13-7-4-8-14-29)19-23-39(24-20-35)21-9-17-34(30-15-16-31(36)32(37)25-30)18-10-22-40(26-34)33(42)28-11-5-3-6-12-28/h3-8,11-16,25H,9-10,17-24,26H2,1-2H3/t34-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = DZOJBGLFWINFBF-UMSFTDKQSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life =
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = 
| pregnancy_category=  
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US          = 
| routes_of_administration =
}}

'''Osanetant''' ('''SR-142,801''') was a [[Tachykinin receptor 3|neurokinin 3]] receptor antagonist developed by [[Sanofi-Synthélabo]], which was being researched for the treatment of [[schizophrenia]], but was discontinued.<ref>{{cite web|title=osanetant Sanofi-Aventis discontinued, France.|url=http://business.highbeam.com/436989/article-1G1-135970821/osanetant-sanofiaventis-discontinued-france|publisher=Highbeam}}</ref><ref>{{cite journal | pmid = 11757797 | volume=2 | issue=7 | title=Osanetant Sanofi-Synth&eacute;labo |date=July 2001 | pages=950–6 | last1 = Kamali | first1 = F | journal = Current opinion in investigational drugs (London, England : 2000)}}</ref> It was the first non-peptide NK<sub>3</sub> antagonist developed in the mid-1990s,<ref>{{cite journal | pmid = 7830490 | volume=56 | issue=1 | title=SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor | year=1995 | pages=PL27–32 | last1 = Emonds-Alt | first1 = X | last2 = Bichon | first2 = D | last3 = Ducoux | first3 = JP | last4 = Heaulme | first4 = M | last5 = Miloux | first5 = B | last6 = Poncelet | first6 = M | last7 = Proietto | first7 = V | last8 = Van Broeck | first8 = D | last9 = Vilain | first9 = P | last10=Neliat | first10=G. | last11=Soubrie´ | first11=P. | last12=Le Fur | first12=G. | last13=Brele`Ere | first13=J.C. | journal = Life Sciences | doi=10.1016/0024-3205(94)00413-M| display-authors=8 }}</ref><ref name="pmid16918326">{{cite journal | author = Quartara L, Altamura M | title = Tachykinin receptors antagonists: from research to clinic | journal = Current Drug Targets | volume = 7 | issue = 8 | pages = 975–92 |date=August 2006 | pmid = 16918326 | doi = 10.2174/138945006778019381| url = http://www.benthamdirect.org/pages/content.php?CDT/2006/00000007/00000008/0007J.SGM | issn = | accessdate = 2011-04-14}}</ref> Other potential applications for osanetant is in the treatment of [[drug addiction]], as it has been found to block the effects of [[cocaine]] in animal models.<ref>{{cite journal | pmid = 16603151 | doi=10.1016/j.ejphar.2006.03.010 | volume=536 | issue=3 | title=The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys |date=May 2006 | pages=269–78 | last1 = Desouzasilva | first1 = M | last2 = Mellojr | first2 = E | last3 = Muller | first3 = C | last4 = Jocham | first4 = G | last5 = Maior | first5 = R | last6 = Huston | first6 = J | last7 = Tomaz | first7 = C | last8 = Barros | first8 = M | journal = European Journal of Pharmacology}}</ref><ref>{{cite journal | pmid = 17004936 | doi=10.1111/j.1460-9568.2006.05041.x | volume=24 | issue=6 | title=Neurokinin receptor antagonism attenuates cocaine's behavioural activating effects yet potentiates its dopamine-enhancing action in the nucleus accumbens core |date=September 2006 | pages=1721–32 | last1 = Jocham | first1 = Gerhard | last2 = Lezoch | first2 = Katharina | last3 = Müller | first3 = Christian P. | last4 = Kart-Teke | first4 = Emriye | last5 = Huston | first5 = Joseph P. | last6 = De Souza Silva | first6 = M. AngéLica | journal = European Journal of Neuroscience}}</ref>

==See also==
* [[Fezolinetant]]
* [[MLE-4901]]
* [[Talnetant]]

==References==
<references/>


{{Neurokinin receptor modulators}}

[[Category:Antipsychotics]]
[[Category:NK3 receptor antagonists]]
[[Category:Benzamides]]
[[Category:Chloroarenes]]
[[Category:Piperidines]]
[[Category:Acetamides]]


{{nervous-system-drug-stub}}